Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 394 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Open Angle Clear all

Conditions: Glaucoma, Open-Angle, Hypertension, Ocular
Interventions: NCX 470, Latanoprost 0.005%; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Glaucoma, Open-Angle, Chronic Wounds
Interventions: Timolol Maleate; Drug
Lead sponsor: VA Northern California Health Care System; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Mather, California

Conditions: Glaucoma, Open-Angle
Interventions: VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle; Drug
Lead sponsor: VivaVision Biotech, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Primary Open-angle Glaucoma
Interventions: iStent; Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Chico, California • Huntington Beach, California • Napa, California + 15 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma
Interventions: PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Artesia, California • Newport Beach, California • Petaluma, California + 15 more

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Interventions: DSLT treatment for Open-Angle Glaucoma, SLT treatment for Open-Angle Glaucoma; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Open Angle Glaucoma
Interventions: Streamline Surgical System, iStent Inject W; Device
Lead sponsor: New World Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 18
States / cities: Fayetteville, Arkansas • Newport Beach, California • Torrance, California + 15 more

Conditions: Ocular Hypertension, Open-Angle Glaucoma
Interventions: Istalol and Optive, Alphagan; Drug
Lead sponsor: Bp Consulting, Inc; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Petaluma, California

Conditions: Glaucoma
Interventions: Brinzolamide 1% and timolol 0.5% fixed combination eye drops; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 20 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Postoperative Complications, Inflammation, Glaucoma, Open-Angle
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 95 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Primary Open Angle Glaucoma
Interventions: Hydrus Aqueous Implant, Cataract surgery; Device · Procedure
Lead sponsor: Ivantis, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 26
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 23 more

Conditions: Primary Open Angle Glaucoma
Interventions: Life Space Questionnaire, Low Luminance Questionnaire, Contrast sensitivity under dim illumination, Visual field under dim illumination (MAIA), Macular Pigment Optical Density (MPOD), Dark Adaptation; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 36
States / cities: Artesia, California • La Jolla, California • Los Angeles, California + 31 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: IOP Lowering Medications; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Honolulu, Hawaii

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Brimonidine Tartrate Ophthalmic Solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 2 Months and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Artesia, California • Sacramento, California • Bel Air, Maryland + 5 more

Conditions: Ocular Hypertension, Open-angle Glaucoma
Interventions: Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty; Drug · Procedure
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 51
States / cities: Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Not listed
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 39
States / cities: Culver City, California • La Jolla, California • Los Angeles, California + 35 more

Conditions: Glaucoma, Ocular Hypertension (OH)
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Springdale, Arkansas • Denver, Colorado • Danbury, Connecticut + 8 more

Conditions: Open Angle Glaucoma
Interventions: Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Prairie Eye Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Glaucoma, Primary Open Angle
Interventions: Caffeine tablet; Dietary Supplement
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years to 90 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Absorption and Safety of Topical Timolol to Treat Chronic Wounds

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

Direct vs. Conventional SLT in Open-Angle Glaucoma: A RCT

STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure

Trial Comparing Ketorolac Tromethamine 0.4% & Prednisolone Acetate 1% in Reducing Post-SLT Anterior Chamber Flare & Cells

Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)

Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Caffeine Consumption in Glaucoma Patients and Healthy Subjects